Influenza Infections after Hematopoietic Stem Cell Transplantation: Risk Factors, Mortality, and the Effect of Antiviral Therapy
Open Access
- 1 November 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (9), 1300-1306
- https://doi.org/10.1086/425004
Abstract
Background. Community-acquired respiratory viruses, such as influenza virus, are thought to be major causes of morbidity and mortality in patients who had undergone hematopoietic stem cell transplantation (HSCT). Risk factors for acquisition, progression to pneumonia, and the effect of antiviral therapy are unknown. Methods. We reviewed records from patients with documented influenza over 12 consecutive respiratory-virus infection seasons at a single transplantation center. Results. From 1 September 1989 through 31 March 2002, influenza virus was isolated from 62 of 4797 persons undergoing HSCT (1.3%); 44 patients had upper respiratory tract infections (URIs) alone, and 18 developed pneumonia. Among patients with influenza virus infection, pneumonia developed more commonly among those infected earlier after transplantation (median, 36 vs. 61 days, P = .04) and those with concurrent lymphopenia. Of the 51 cases that were initially diagnosed as URIs, 17 were treated with antivirals, and 34 were not treated. Six untreated patients (18%) developed pneumonia, whereas 1 (13%) of 8 patients treated with rimantadine and 0 of 9 treated with oseltamivir developed pneumonia. The duration of influenza virus shedding was longer in patients treated with steroid doses of >1 mg/kg than among those treated with doses of P < .08). The 30-day mortality rate was highest among patients who had progression to pneumonia (5 [28%] of 18 patients); pulmonary copathogens (such as Aspergillus fumigatus) were commonly isolated. Conclusions. Influenza virus infection is an important cause of mortality early after HSCT. Our nonrandomized data suggest that early antiviral therapy with neuraminidase inhibitors may prevent progression to pneumonia and decrease viral shedding, which may prevent both influenza-related death in index patients and nosocomial transmission to others.This publication has 18 references indexed in Scilit:
- Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantationBone Marrow Transplantation, 2003
- Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trialsBMJ, 2003
- Low mortality rates related to respiratory virus infections after bone marrow transplantationBone Marrow Transplantation, 2003
- Prolonged Shedding of Multidrug-Resistant Influenza A Virus in an Immunocompromised PatientThe New England Journal of Medicine, 2003
- Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factorsBlood, 2002
- Viral infections in immunocompromised patients: whatʼs new with respiratory viruses?Current Opinion in Infectious Diseases, 2002
- The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantationBone Marrow Transplantation, 2002
- Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow TransplantationBone Marrow Transplantation, 2001
- Common Emergence of Amantadine‐ and Rimantadine‐Resistant Influenza A Viruses in Symptomatic Immunocompromised AdultsClinical Infectious Diseases, 1998
- Influenza A in Immunocompromised PatientsClinical Infectious Diseases, 1993